Eintrag weiter verarbeiten
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Journal of Clinical Oncology, 30, 2012, 15_suppl, S. e14563-e14563 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto |
|---|---|
| author |
Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto |
| spellingShingle |
Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto Journal of Clinical Oncology Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. Cancer Research Oncology |
| author_sort |
vitale, alessandro |
| spelling |
Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14563 <jats:p> e14563 </jats:p><jats:p> Background: Patients with intermediate stage hepatocellular carcinoma (HCC) obtaining an unsatisfactory response after loco regional (LR) therapies are at high risk of drop-out from a new chance of LR treatment or progression to advanced-terminal stages of disease. We prospectively used Sorafenib in this particular category of patients as a bridge therapy. The aim was to decrease the risk of tumour progression and to make them again eligible for loco regional therapies. Methods: Primary endpoint: disease control (DC) with Sorafenib, defined as complete/partial response or stable disease as by the modified RECIST criteria, maintained for ≥ 28 days from the first indications of response. Secondary endpoints: proportion of patients progression free at 2 months; median overall and progression free survivals. Patients obtaining DC with Sorafenib were again considered eligible for LR therapy. Inclusion criteria: a) intermediate stage; b) Child Pugh class A; c) performance status 0; d) unsatisfactory response to LR therapies (resection, ablation, chemoembolization), defined as incomplete response after at least 2 LR therapies. Study period: 01/04/2008–31/10/2011. End of follow-up: 31/01/2012. Results: Forty one patients were enrolled according to the study design. Thirty seven patients (90%) were progression free at the 2 months evaluation. A persistent DC was obtained in 29 patients (71%). According to the study hypothesis these patients were considered again eligible for loco regional therapies: 19 patients (65%) had ablation ± chemoembolization; 6 had liver transplantation (22%); 3 had liver resection (13%); 1 had radioembolization. Median duration of therapy with Sorafenib was 5 months (1–22). Sixteen patients (55%) had Sorafenib therapy both before and after LR therapy. Fourteen patients (48%) had more than one LR procedure. Median survival was 21 months (range, 1–39) in the whole group, while it was 25 months (range, 2–39) in the DC subgroup (median time to progression = 21 months, range 2–39). Conclusions: Sorafenib achieves high DC rates in BCLC B HCC patients with unsatisfactory response to LR therapies making them again eligible for LR therapies. </jats:p> Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2012.30.15_suppl.e14563 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC5lMTQ1NjM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC5lMTQ1NjM |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2012 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
vitale2012sorafenibasbridgingtherapyinpatientswithintermediatehepatocellularcarcinoma |
| publishDateSort |
2012 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_unstemmed |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_full |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_fullStr |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_full_unstemmed |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_short |
Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_sort |
sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14563 |
| publishDate |
2012 |
| physical |
e14563-e14563 |
| description |
<jats:p> e14563 </jats:p><jats:p> Background: Patients with intermediate stage hepatocellular carcinoma (HCC) obtaining an unsatisfactory response after loco regional (LR) therapies are at high risk of drop-out from a new chance of LR treatment or progression to advanced-terminal stages of disease. We prospectively used Sorafenib in this particular category of patients as a bridge therapy. The aim was to decrease the risk of tumour progression and to make them again eligible for loco regional therapies. Methods: Primary endpoint: disease control (DC) with Sorafenib, defined as complete/partial response or stable disease as by the modified RECIST criteria, maintained for ≥ 28 days from the first indications of response. Secondary endpoints: proportion of patients progression free at 2 months; median overall and progression free survivals. Patients obtaining DC with Sorafenib were again considered eligible for LR therapy. Inclusion criteria: a) intermediate stage; b) Child Pugh class A; c) performance status 0; d) unsatisfactory response to LR therapies (resection, ablation, chemoembolization), defined as incomplete response after at least 2 LR therapies. Study period: 01/04/2008–31/10/2011. End of follow-up: 31/01/2012. Results: Forty one patients were enrolled according to the study design. Thirty seven patients (90%) were progression free at the 2 months evaluation. A persistent DC was obtained in 29 patients (71%). According to the study hypothesis these patients were considered again eligible for loco regional therapies: 19 patients (65%) had ablation ± chemoembolization; 6 had liver transplantation (22%); 3 had liver resection (13%); 1 had radioembolization. Median duration of therapy with Sorafenib was 5 months (1–22). Sixteen patients (55%) had Sorafenib therapy both before and after LR therapy. Fourteen patients (48%) had more than one LR procedure. Median survival was 21 months (range, 1–39) in the whole group, while it was 25 months (range, 2–39) in the DC subgroup (median time to progression = 21 months, range 2–39). Conclusions: Sorafenib achieves high DC rates in BCLC B HCC patients with unsatisfactory response to LR therapies making them again eligible for LR therapies. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
0 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792320762238992386 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T10:51:17.203Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Sorafenib+as+bridging+therapy+in+patients+with+intermediate+hepatocellular+carcinoma.&rft.date=2012-05-20&genre=article&issn=1527-7755&volume=30&issue=15_suppl&pages=e14563-e14563&jtitle=Journal+of+Clinical+Oncology&atitle=Sorafenib+as+bridging+therapy+in+patients+with+intermediate+hepatocellular+carcinoma.&aulast=Cillo&aufirst=Umberto&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.15_suppl.e14563&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792320762238992386 |
| author | Vitale, Alessandro, Lombardi, Giuseppe, Ramirez Morales, Rafael, Lonardi, Sara, Zanus, Giacomo, Zagonel, Vittorina, Cillo, Umberto |
| author_facet | Vitale, Alessandro, Lombardi, Giuseppe, Ramirez Morales, Rafael, Lonardi, Sara, Zanus, Giacomo, Zagonel, Vittorina, Cillo, Umberto, Vitale, Alessandro, Lombardi, Giuseppe, Ramirez Morales, Rafael, Lonardi, Sara, Zanus, Giacomo, Zagonel, Vittorina, Cillo, Umberto |
| author_sort | vitale, alessandro |
| container_issue | 15_suppl |
| container_start_page | 0 |
| container_title | Journal of Clinical Oncology |
| container_volume | 30 |
| description | <jats:p> e14563 </jats:p><jats:p> Background: Patients with intermediate stage hepatocellular carcinoma (HCC) obtaining an unsatisfactory response after loco regional (LR) therapies are at high risk of drop-out from a new chance of LR treatment or progression to advanced-terminal stages of disease. We prospectively used Sorafenib in this particular category of patients as a bridge therapy. The aim was to decrease the risk of tumour progression and to make them again eligible for loco regional therapies. Methods: Primary endpoint: disease control (DC) with Sorafenib, defined as complete/partial response or stable disease as by the modified RECIST criteria, maintained for ≥ 28 days from the first indications of response. Secondary endpoints: proportion of patients progression free at 2 months; median overall and progression free survivals. Patients obtaining DC with Sorafenib were again considered eligible for LR therapy. Inclusion criteria: a) intermediate stage; b) Child Pugh class A; c) performance status 0; d) unsatisfactory response to LR therapies (resection, ablation, chemoembolization), defined as incomplete response after at least 2 LR therapies. Study period: 01/04/2008–31/10/2011. End of follow-up: 31/01/2012. Results: Forty one patients were enrolled according to the study design. Thirty seven patients (90%) were progression free at the 2 months evaluation. A persistent DC was obtained in 29 patients (71%). According to the study hypothesis these patients were considered again eligible for loco regional therapies: 19 patients (65%) had ablation ± chemoembolization; 6 had liver transplantation (22%); 3 had liver resection (13%); 1 had radioembolization. Median duration of therapy with Sorafenib was 5 months (1–22). Sixteen patients (55%) had Sorafenib therapy both before and after LR therapy. Fourteen patients (48%) had more than one LR procedure. Median survival was 21 months (range, 1–39) in the whole group, while it was 25 months (range, 2–39) in the DC subgroup (median time to progression = 21 months, range 2–39). Conclusions: Sorafenib achieves high DC rates in BCLC B HCC patients with unsatisfactory response to LR therapies making them again eligible for LR therapies. </jats:p> |
| doi_str_mv | 10.1200/jco.2012.30.15_suppl.e14563 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC5lMTQ1NjM |
| imprint | American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2012 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T10:51:17.203Z |
| match_str | vitale2012sorafenibasbridgingtherapyinpatientswithintermediatehepatocellularcarcinoma |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | e14563-e14563 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Vitale, Alessandro Lombardi, Giuseppe Ramirez Morales, Rafael Lonardi, Sara Zanus, Giacomo Zagonel, Vittorina Cillo, Umberto 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14563 <jats:p> e14563 </jats:p><jats:p> Background: Patients with intermediate stage hepatocellular carcinoma (HCC) obtaining an unsatisfactory response after loco regional (LR) therapies are at high risk of drop-out from a new chance of LR treatment or progression to advanced-terminal stages of disease. We prospectively used Sorafenib in this particular category of patients as a bridge therapy. The aim was to decrease the risk of tumour progression and to make them again eligible for loco regional therapies. Methods: Primary endpoint: disease control (DC) with Sorafenib, defined as complete/partial response or stable disease as by the modified RECIST criteria, maintained for ≥ 28 days from the first indications of response. Secondary endpoints: proportion of patients progression free at 2 months; median overall and progression free survivals. Patients obtaining DC with Sorafenib were again considered eligible for LR therapy. Inclusion criteria: a) intermediate stage; b) Child Pugh class A; c) performance status 0; d) unsatisfactory response to LR therapies (resection, ablation, chemoembolization), defined as incomplete response after at least 2 LR therapies. Study period: 01/04/2008–31/10/2011. End of follow-up: 31/01/2012. Results: Forty one patients were enrolled according to the study design. Thirty seven patients (90%) were progression free at the 2 months evaluation. A persistent DC was obtained in 29 patients (71%). According to the study hypothesis these patients were considered again eligible for loco regional therapies: 19 patients (65%) had ablation ± chemoembolization; 6 had liver transplantation (22%); 3 had liver resection (13%); 1 had radioembolization. Median duration of therapy with Sorafenib was 5 months (1–22). Sixteen patients (55%) had Sorafenib therapy both before and after LR therapy. Fourteen patients (48%) had more than one LR procedure. Median survival was 21 months (range, 1–39) in the whole group, while it was 25 months (range, 2–39) in the DC subgroup (median time to progression = 21 months, range 2–39). Conclusions: Sorafenib achieves high DC rates in BCLC B HCC patients with unsatisfactory response to LR therapies making them again eligible for LR therapies. </jats:p> Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. Journal of Clinical Oncology |
| spellingShingle | Vitale, Alessandro, Lombardi, Giuseppe, Ramirez Morales, Rafael, Lonardi, Sara, Zanus, Giacomo, Zagonel, Vittorina, Cillo, Umberto, Journal of Clinical Oncology, Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma., Cancer Research, Oncology |
| title | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_full | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_fullStr | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_full_unstemmed | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_short | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_sort | sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| title_unstemmed | Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14563 |